Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

被引：38

作者：

Rossi, Ernesto ^{[1
]}

Schinzari, Giovanni ^{[1
,2
]}

Zizzari, Ilaria Grazia ^{[3
]}

Maiorano, Brigida Anna ^{[1
]}

Pagliara, Monica Maria ^{[4
]}

Sammarco, Maria Grazia ^{[4
]}

Fiorentino, Vincenzo ^{[5
]}

Petrone, Gianluigi ^{[5
]}

Cassano, Alessandra ^{[1
,2
]}

Rindi, Guido ^{[5
]}

Bria, Emilio ^{[1
,2
]}

Blasi, Maria Antonietta ^{[4
]}

Nuti, Marianna ^{[3
]}

Tortora, Giampaolo ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ, A Gemelli IRCCS, Med Oncol, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy

[3] Sapienza Univ, Dept Expt Med, Lab Tumor Immunol & Cell Therapy, Policlin Umberto 1, I-00162 Rome, Italy

[4] Fdn Policlin Univ, A Gemelli IRCCS, Ophtalmol, I-00168 Rome, Italy

[5] Fdn Policlin Univ, A Gemelli IRCCS, Pathol, I-00168 Rome, Italy

来源：

CANCERS | 2019年 / 11卷 / 08期

关键词：

immunotherapy; uveal melanoma; checkpoint inhibitors; PD-L1; nivolumab; pembrolizumab; ipilimumab; IDO; TUMOR-INFILTRATING LYMPHOCYTES; MIGRATION-INHIBITORY FACTOR; CANDIDATE PROTEINS GP100; ANTIGEN EXPRESSION; ADOPTIVE TRANSFER; HLA EXPRESSION; CELL-ACTIVITY; MONOSOMY; CLASS-I; IPILIMUMAB;

D O I：

10.3390/cancers11081055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.

引用

页数：12

共 50 条

[1] Immunotherapy for uveal melanoma
Kim, Dae Won
Anderson, Jaime
Patel, Sapna P.
MELANOMA MANAGEMENT, 2016, 3 (02) : 125 - 135
[2] Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma
Venza, Mario
Visalli, Maria
Catalano, Teresa
Beninati, Concetta
Teti, Diana
Venza, Isabella
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (02) : 190 - 205
[3] Uveal melanoma: Recent advances in immunotherapy
Sorrentino, Francesco Saverio
De Rosa, Francesco
Di Terlizzi, Patrick
Toneatto, Giacomo
Gabai, Andrea
Finocchio, Lucia
Salati, Carlo
Spadea, Leopoldo
Zeppieri, Marco
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (01):
[4] Immunological profiling of liver metastasis of uveal melanoma
Wilson, Matthew W.
Cernichiaro-Espinosa, Linda A.
Choi, Sue
Allen-Winters, Stephanie
Yang, Chuan He
Pfeffer, Lawrence
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[5] Dual Immunological Checkpoint Blockade for Uveal Melanoma
Khan, Shaheer
Carvajal, Richard D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 554 - +
[6] Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Castet, Florian
Garcia-Mulero, Sandra
Sanz-Pamplona, Rebeca
Cuellar, Andres
Casanovas, Oriol
Maria Caminal, Josep
Maria Piulat, Josep
CANCERS, 2019, 11 (06):
[7] Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Fu, Yihang
Xiao, Wei
Mao, Yuxiang
CANCERS, 2022, 14 (13)
[8] Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy
Orloff, Marlana
OCULAR ONCOLOGY AND PATHOLOGY, 2021, 7 (03) : 168 - 176
[9] Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Kastelan, Snjezana
Antunica, Antonela Gverovic
Oreskovic, Lidija Beketic
Pelcic, Goran
Kasun, Ema
Hat, Koraljka
CURRENT MEDICINAL CHEMISTRY, 2020, 27 (08) : 1350 - 1366
[10] PRAME: a potential target for immunotherapy in uveal melanoma
Gezgin, Gulcin
Luk, Sietse J.
Cao, Jinfeng
Dogrusoz, Mehmet
Krijgsman, Danielle
van der Velden, Pieter A.
Luyten, Gregorius P. M.
Harbour, J. William
Jordanova, Ekaterina S.
Heemskerk, Mirjam H. M.
Jager, Martine J.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)

← 1 2 3 4 5 →